Dataset Information

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

ABSTRACT: This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).

DISEASE(S): Neuroendocrine Tumors,Sarcoma,Anaplastic Thyroid Cancer,Small Cell Lung Cancer,Thyroid Carcinoma, Anaplastic,Colorectal Cancer,Small Cell Lung Carcinoma,Small Cell Lung Cancer Metastatic,Soft Tissue Sarcoma,Neoplasms,Metastatic Solid Tumor,Gastric Cancer,Neuroendocrine Tumour,Tumores Sólidos Avanzados

PROVIDER: 2353932 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:Interventions: Group 1: letter version 1, brochure version 1; The study consists of two parts: in part one (during the first year) participants receive conventional medical consulting. In the second part (years two and three) only physiscians with a special training can participate in the study. Group 2: letter version 1, brochure version 2; The study consists of two parts: in part one (during the first year) participants receive conventional medical consulting. In the second part (years two and three) only physiscians with a special training can participate in the study. Group 3: letter version 1, brochure version 3; The study consists of two parts: in part one (during the first year) participants receive conventional medical consulting. In the second part (years two and three) only physiscians with a special training can participate in the study. Group 4: letter version 2, brochure version 1; The study consists of two parts: in part one (during the first year) participants receive conventional medical consulting. In the second part (years two and three) only physiscians with a special training can participate in the study. Group 5: letter version 2, brochure version 2; The study consists of two parts: in part one (during the first year) participants receive conventional medical consulting. In the second part (years two and three) only physiscians with a special training can participate in the study. Group 6: letter version 2, brochure version 3; The study consists of two parts: in part one (during the first year) participants receive conventional medical consulting. In the second part (years two and three) only physiscians with a special training can participate in the study. Primary outcome(s): informed decion in terms of participating in colorectal cancer screening (standardized questionnaire, Steckelberg et al.), assessed 3 months after distribution of screening information Study Design: Allocation: Non-randomized controlled study; Masking: Open (masking not used); Control: active; Assignment: other; Study design purpose: screening

Dataset Information

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure